HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sgouros, G. Articles by Mohan, R. Search for Related Content PubMed PubMed Citation Articles by Sgouros, G. Articles by Mohan, R.

Three-Dimensional Dosimetry for Radioimmunotherapy Treatment Planning

Department of Medical Physics and Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: For correspondence or reprints contact: George Sgouros, PhD, Dept. of Medical Physics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York NY 10021.

ABSTRACT

Absorbed-dose calculations for radioimmunotherapy are generally based on tracer imaging studies of the labeled antibody. Such calculations yield estimates of the average dose to normal and target tissues assuming idealized geometries for both the radioactivity source volume and the target volume. This work describes a methodology that integrates functional information obtained from SPECT or PET with anatomical information from CT or MRI. These imaging modalities are used to define the actual shape and position of the radioactivity source volume relative to the patient's anatomy. This information is then used to calculate the spatially varying absorbed dose, depicted in "colorwash" superimposed on the anatomical imaging study. By accounting for individuaI uptake characteristics of a particular tumor and/or normal tissue volume and superimposing resulting absorbed-dose distribution over patient anatomy, this approach provides a patient-specific assessment of the target-to-surrounding normal tissue absorbed-dose ratio. Such information is particularly important in a treatment planning approach to radioimmunotherapy, wherein a therapeutic administration of antibody is preceded by a tracer imaging study to assess therapeutic benefit.

This article has been cited by other articles:

				R. W. Howell, P. V. S. V. Neti, M. Pinto, B. I. Gerashchenko, V. R. Narra, and E. I. Azzam Challenges and progress in predicting biological responses to incorporated radioactivity Radiat Prot Dosimetry, December 1, 2006; 122(1-4): 521 - 527. [Abstract] [Full Text] [PDF]

				M. G. Stabin, T. E. Peterson, G. E. Holburn, and M. A. Emmons Voxel-Based Mouse and Rat Models for Internal Dose Calculations J. Nucl. Med., April 1, 2006; 47(4): 655 - 659. [Abstract] [Full Text] [PDF]

				G. Sgouros Dosimetry of Internal Emitters J. Nucl. Med., January 1, 2005; 46(1_suppl): 18S - 27S. [Abstract] [Full Text] [PDF]

				G. Sgouros, S. Squeri, A. M. Ballangrud, K. S. Kolbert, J. B. Teitcher, K. S. Panageas, R. D. Finn, C. R. Divgi, S. M. Larson, and A. D. Zelenetz Patient-Specific, 3-Dimensional Dosimetry in Non-Hodgkin's Lymphoma Patients Treated with 131I-anti-B1 Antibody: Assessment of Tumor Dose-Response J. Nucl. Med., February 1, 2003; 44(2): 260 - 268. [Abstract] [Full Text] [PDF]

				M. E. Juweid Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice J. Nucl. Med., November 1, 2002; 43(11): 1507 - 1529. [Abstract] [Full Text] [PDF]

				M. Ljungberg, K. Sjogreen, X. Liu, E. Frey, Y. Dewaraja, and S.-E. Strand A 3-Dimensional Absorbed Dose Calculation Method Based on Quantitative SPECT for Radionuclide Therapy: Evaluation for 131I Using Monte Carlo Simulation J. Nucl. Med., August 1, 2002; 43(8): 1101 - 1109. [Abstract] [Full Text] [PDF]

				K. K. Matthay, C. Panina, J. Huberty, D. Price, D. V. Glidden, H. R. Tang, R. A. Hawkins, J. Veatch, and B. Hasegawa Correlation of Tumor and Whole-Body Dosimetry with Tumor Response and Toxicity in Refractory Neuroblastoma Treated with 131I-MIBG J. Nucl. Med., November 1, 2001; 42(11): 1713 - 1721. [Abstract] [Full Text] [PDF]

				W. Wang, S. M. Larson, M. Fazzari, S. K. Tickoo, K. Kolbert, G. Sgouros, H. Yeung, H. Macapinlac, J. Rosai, and R. J. Robbins Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomographic Scanning in Patients with Thyroid Cancer J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1107 - 1113. [Abstract] [Full Text]